Metagenomi Therapeutics Statistics
Total Valuation
MGX has a market cap or net worth of $49.32 million. The enterprise value is -$50.15 million.
Important Dates
The last earnings date was Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MGX has 37.65 million shares outstanding. The number of shares has increased by 1.06% in one year.
| Current Share Class | 37.65M |
| Shares Outstanding | 37.65M |
| Shares Change (YoY) | +1.06% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 10.49% |
| Owned by Institutions (%) | 19.78% |
| Float | 27.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.28 |
| Forward PS | 1.73 |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.43, with a Debt / Equity ratio of 0.28.
| Current Ratio | 6.43 |
| Quick Ratio | 6.23 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.02% and return on invested capital (ROIC) is -26.72%.
| Return on Equity (ROE) | -49.02% |
| Return on Assets (ROA) | -23.44% |
| Return on Invested Capital (ROIC) | -26.72% |
| Return on Capital Employed (ROCE) | -53.18% |
| Weighted Average Cost of Capital (WACC) | 4.40% |
| Revenue Per Employee | $187,655 |
| Profits Per Employee | -$721,748 |
| Employee Count | 119 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -146,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.67% in the last 52 weeks. The beta is 0.64, so MGX's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -12.67% |
| 50-Day Moving Average | 1.43 |
| 200-Day Moving Average | 1.82 |
| Relative Strength Index (RSI) | 37.86 |
| Average Volume (20 Days) | 174,069 |
Short Selling Information
The latest short interest is 1.87 million, so 4.97% of the outstanding shares have been sold short.
| Short Interest | 1.87M |
| Short Previous Month | 2.17M |
| Short % of Shares Out | 4.97% |
| Short % of Float | 6.84% |
| Short Ratio (days to cover) | 9.66 |
Income Statement
In the last 12 months, MGX had revenue of $22.33 million and -$85.89 million in losses. Loss per share was -$2.30.
| Revenue | 22.33M |
| Gross Profit | -72.10M |
| Operating Income | -92.78M |
| Pretax Income | -86.03M |
| Net Income | -85.89M |
| EBITDA | -87.55M |
| EBIT | -92.78M |
| Loss Per Share | -$2.30 |
Full Income StatementBalance Sheet
The company has $140.16 million in cash and $39.19 million in debt, with a net cash position of $100.98 million or $2.68 per share.
| Cash & Cash Equivalents | 140.16M |
| Total Debt | 39.19M |
| Net Cash | 100.98M |
| Net Cash Per Share | $2.68 |
| Equity (Book Value) | 137.79M |
| Book Value Per Share | 3.66 |
| Working Capital | 122.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$87.23 million and capital expenditures -$311,000, giving a free cash flow of -$87.54 million.
| Operating Cash Flow | -87.23M |
| Capital Expenditures | -311,000 |
| Depreciation & Amortization | 5.23M |
| Net Borrowing | n/a |
| Free Cash Flow | -87.54M |
| FCF Per Share | -$2.33 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -415.48% |
| Pretax Margin | -385.27% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MGX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.06% |
| Shareholder Yield | -1.06% |
| Earnings Yield | -168.99% |
| FCF Yield | -172.24% |
Analyst Forecast
The average price target for MGX is $9.00, which is 587.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 587.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 48.86% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
